Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.

Purpose: The purpose of this study was to evaluate the safety, dosimetry, and apparent receptor occupancy (RO) of [(64)Cu]DOTA-patritumab, a radiolabeled monoclonal antibody directed against HER3/ERBB3 in subjects with advanced solid tumors.Procedures: Dosimetry subjects (n = 5) received [(64)Cu]DOT...

Descripción completa

Detalles Bibliográficos

Publicado en:	Molecular Imaging & Biology Vol. 18; no. 3; pp. 446 - 454
Autores principales:	Lockhart, A., Liu, Yongjian, Dehdashti, Farrokh, Laforest, Richard, Picus, Joel, Frye, Jennifer, Trull, Lauren, Belanger, Stefanie, Desai, Madhuri, Mahmood, Syed, Mendell, Jeanne, Welch, Michael, Siegel, Barry, Lockhart, A Craig, Welch, Michael J, Siegel, Barry A
Formato:	clinical trial research Journal Article
Publicado:	Springer Nature Jun2016
Acceso en línea:	Ver este registro en EBSCOhost